Back
ESC Professional Premium Access

Comparing coronary artery plaque regression in patients treated with ezetimibe or PCSK9 inhibitors following acute coronary syndrome: a systematic review and meta-analysis

Session: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations
Topic: Lipid-Lowering Agents
Speaker: Doctor T. Fujisaki (Osaka, JP)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Tomohiro Fujisaki

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)
0 follower

9 more presentations in this session

Discussant - Dyslipidaemias: current strategies and innovations

Access
Like
Thumbnail

The efficacy and safety of low-intensity statins for high bleeding risk patients after PCI in Asian populations

Speaker: Doctor Z. Zhang (Tianjin, CN)

Access
Abstract
Slides
Video
Like
Thumbnail

Statin users have lower fatty acid oxidative metabolisms in muscle mitochondria and have a higher content of long-chain and medium-chain acylcarnitines in muscles.

Speaker: Doctor E. Bolsteina (Riga, LV)

Access
Abstract
Slides
Like
Thumbnail

The efficacy of tafolecimab in lipoprotein(a) reductions in hypercholesterolaemic patients: a pooled analysis of three phase 3 trials

Speaker: Ms H. Shen (Beijing, CN)

Access
Abstract
Slides
Video
Like
Thumbnail

Efficacy and metabolic impact of combination therapy vs. high-intensity statin monotherapy: an exploratory analysis of the Save SAMS Trial

Speaker: Professor S. Hong (Seoul, KR)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

Speakers: Doctor T. Fujisaki, Doctor Z. Zhang, Doctor E. Bolsteina, Ms H. Shen, Professor S. Hong
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

novartis Explore sponsored resources